Key result
Persistent iASD occurs in ~5% post-transseptal puncture without link to sheath size or atrial cardiomyopathy.
Why the study?
The predictors of persistent iatrogenic atrial septal defects after transseptal puncture for left atrial access, including fibrotic atrial cardiomyopathy and mitral valve regurgitation, were unclear.
Do fibrotic atrial cardiomyopathy, mitral valve regurgitation, or transseptal sheath size predict the development of persistent iatrogenic atrial septal defects in patients undergoing transseptal puncture for recurrent atrial tachyarrhythmia ablation?
Cohort (n=149)
Do fibrotic atrial cardiomyopathy, mitral valve regurgitation, or transseptal sheath size predict the development of persistent iatrogenic atrial septal defects in patients undergoing transseptal puncture for recurrent atrial tachyarrhythmia ablation?
Persistent iatrogenic atrial septal defects following transseptal puncture for left atrial ablation are uncommon (5.4%) and are not predicted by transseptal sheath size, fibrotic atrial cardiomyopathy, or mitral regurgitation.
Iatrogenic ASDs remain uncommon after transseptal puncture without links to sheath size or fibrosis markers; leaves open alternative predictors in ablation cohorts.
BACKGROUND: Transseptal puncture (TSP) for left atrial access is routinely used during various cardiac interventions, including ablation for atrial tachyarrhythmia. However, in selected patients, subsequent iatrogenic atrial septal defects (iASD) persist. This study determines whether fibrotic atrial cardiomyopathy (FACM) or mitral valve regurgitation (MR) are predictors of persistent iASD development post-TSP. METHODS: We analyzed data from patients undergoing radiofrequency ablation with high-density electroanatomical mapping for recurrent atrial tachyarrhythmias after a primary pulmonary vein isolation using either cryo or RF technologies. Patients were categorized based on transesophageal echocardiography findings: (1) competent atrial septum (cAS) (2), iASD, or (3) a patent foramen ovale (PFO). Differences in FACM and MR were assessed across these groups. RESULTS: Of 149 patients (age 67.7 ± 9.7 years), 125 (83.9%) had cAS, 8 (5.4%) iASD, and 16 (10.7%) PFO. No significant differences were observed in age (p = 0.932), BMI (p = 0.612), or LVEF (p = 0.581). The TSP sheath size was not associated with iASD occurrence (p = 0.857). Common surrogates of FACM, i.e., LAVI (p = 0.114), LA area (p = 0.156), mean left atrial pressure (LAP; p = 0.459), or total low-voltage area burden (p = 0.058) did not differ significantly among groups. MR was not linked to increased LAP (at first (p = 0.290) and second procedure (p = 0.212)) or a higher incidence of iASD (at first (p = 0.155) and second procedure (p = 0.917)). Mean LAP did not correlate with LA size (p = 0.471) or low-voltage extent (p = 0.084). CONCLUSION: Our findings underscore that iASDs post-TSP for left atrial ablation are uncommon and unrelated to TSP sheath size, FACM, or MR, further minimizing concerns for routine interventions in patients with more advanced arrhythmia substrate or valvular disease.
No takes yet. Share an insight, caveat, or question.
Heil et al. (2025) conducted a cohort in Recurrent atrial tachyarrhythmias (n=149). Fibrotic atrial cardiomyopathy, mitral valve regurgitation, and transseptal sheath size vs. Absence of these risk factors was evaluated on Persistence of iatrogenic atrial septal defect (iASD). Persistent iatrogenic atrial septal defects post-transseptal puncture occurred in 5.4% of patients and were not associated with sheath size, fibrotic atrial cardiomyopathy, or mitral regurgitation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: